- Home
- CARV vs SNGX Comparison
CARV vs SNGX Comparison
Compare CARV & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARV
- SNGX
- Stock Information
- Founded
- CARV 1948
- SNGX 1987
- Country
- CARV United States
- SNGX United States
- Employees
- CARV N/A
- SNGX N/A
- Industry
- CARV Savings Institutions
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- CARV Finance
- SNGX Health Care
- Exchange
- CARV Nasdaq
- SNGX Nasdaq
- Market Cap
- CARV 14.5M
- SNGX 13.8M
- IPO Year
- CARV 1994
- SNGX 1987
- Fundamental
- Price
- CARV $3.14
- SNGX $1.38
- Analyst Decision
- CARV
- SNGX Strong Buy
- Analyst Count
- CARV 0
- SNGX 1
- Target Price
- CARV N/A
- SNGX $6.00
- AVG Volume (30 Days)
- CARV 19.6K
- SNGX 490.4K
- Earning Date
- CARV 11-13-2025
- SNGX 11-10-2025
- Dividend Yield
- CARV N/A
- SNGX N/A
- EPS Growth
- CARV N/A
- SNGX N/A
- EPS
- CARV N/A
- SNGX N/A
- Revenue
- CARV $22,032,000.00
- SNGX N/A
- Revenue This Year
- CARV N/A
- SNGX N/A
- Revenue Next Year
- CARV N/A
- SNGX N/A
- P/E Ratio
- CARV N/A
- SNGX N/A
- Revenue Growth
- CARV N/A
- SNGX N/A
- 52 Week Low
- CARV $1.30
- SNGX $1.09
- 52 Week High
- CARV $3.85
- SNGX $6.23
- Technical
- Relative Strength Index (RSI)
- CARV 69.99
- SNGX 36.49
- Support Level
- CARV $2.67
- SNGX $1.30
- Resistance Level
- CARV $2.89
- SNGX $1.61
- Average True Range (ATR)
- CARV 0.17
- SNGX 0.09
- MACD
- CARV 0.02
- SNGX 0.01
- Stochastic Oscillator
- CARV 98.04
- SNGX 17.39
About CARV Carver Bancorp Inc.
Carver Bancorp Inc is a holding company and conducts its business as a unitary saving and loan holding firm and the business of the company consists of the operation of its subsidiary. The bank offers a wide range of financial solutions to meet customers' banking. It offers other consumer and commercial banking products and services, such as debit cards, online banking, online bill pay, and telephone banking. The company provides deposit products, such as demand, savings, and time deposits for consumers, businesses, and governmental and quasi-governmental agencies in its market area within New York City.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).